Merck Sharp + Dohme Corp.

Arrowhead Pharmaceuticals, Inc.

Patrick Shao

Paul E Finke

Jianming Bao

F Anthony Romero

Feroze Ujjainwalla

Zhen Li

Harold B Wood

Weiguo Liu

Rui Zhu

Joseph Leslie Duffy

Jonathan D Benson

Feng Ye

Edward C Sherer

Sriram Tyagarajan

Debra L Ondeyka

Yi Zang

Remond Moningka

Zahid Hussain

Erik W Bush

Xiaokai Li

Matthew Fowler-Watters

Revathi Reddy Katipally

Michael A Plotkin

Aaron Zwicker

Dongxu Shu

Joseph L Duffy

Zahid Hussian

Anthony Romero

Synthetic &#x3b1;v&#x3b2;6 integrin ligands of Formula I having serum stability and affinity for integrin &#x3b1;v&#x3b2;6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin &#x3b1;v&#x3b2;6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include &#x3b1;v&#x3b2;6 integrin ligands and methods of use are also described. 

Integrin ligands and uses thereof

Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety. 

Spiroxazolidinone compounds

Growing community of inventors

Fanwood, NJ, United States of America

Patrick Shao